文献速递临床试验与 GCP基础与转化研究

随机试验中淀粉样蛋白水平降低对认知变化的影响:工具变量荟萃分析

Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
PubMed 文献 · BMJ · 2021-02-25

该工具变量荟萃分析纳入14项针对淀粉样蛋白机制的阿尔茨海默病预防或治疗随机对照试验,评估淀粉样蛋白水平降低是否改善认知。汇总结果显示,淀粉样蛋白水平每降低0.1标准化摄取值比单位,简易精神状态检查评分仅改善0.03分(95%CI -0.06至0.1),表明降低淀粉样蛋白的策略并未显著改善认知。

要点

  • 淀粉样蛋白水平每降低0.1 SUVR单位,MMSE评分改善仅0.03分(95%CI -0.06至0.1)。
  • 汇总证据来自14项随机对照试验,精度高于任一单项试验。
  • 现有证据不支持降低淀粉样蛋白可实质性改善认知。

核心结论

  • 汇总现有报告淀粉样蛋白水平降低和认知变化的试验证据,降低淀粉样蛋白的策略并未实质性改善认知。

研究设计与样本

  • 工具变量荟萃分析,纳入14项针对淀粉样蛋白机制的阿尔茨海默病预防或治疗随机对照试验,试验从ClinicalTrials.gov识别。
  • 纳入分析需同时获得淀粉样蛋白正电子发射断层扫描测量的脑淀粉样蛋白水平变化和每个随机化组至少一项认知测试评分变化的信息。

主要发现

  • 14项随机对照试验的汇总结果比任何单项试验的估计更精确。
  • 淀粉样蛋白水平降低0.1标准化摄取值比单位的汇总效应为简易精神状态检查评分改善0.03分(95%置信区间-0.06至0.1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate trials of drugs that target amyloid to determine whether reductions in amyloid levels are likely to improve cognition. DESIGN: Instrumental variable meta-analysis. SETTING: 14 randomized controlled trials of drugs for the prevention or treatment of Alzheimer's disease that targeted an amyloid mechanism, identified from ClinicalTrials.gov. POPULATION: Adults enrolled in randomized controlled trials of amyloid targeting drugs. Inclusion criteria for trials vary, but typically include adults aged 50 years or older with a diagnosis of mild cognitive impairment or Alzheimer's disease, and amyloid positivity at baseline. MAIN OUTCOME MEASURES: Analyses included trials for which information could be obtained on both change in brain amyloid levels measured with amyloid positron emission tomography and change in at least one cognitive test score reported for each randomization arm. RESULTS: Pooled results from the 14 randomized controlled trials were more precise than estimates from any single trial. The pooled estimate for the effect of reducing amyloid levels by 0.1 standardized uptake value ratio units was an improvement in the mini-mental state examination score of 0.03 (95% confidence interval -0.06 to 0.1) points. This study provides a web application that allows for the re-estimation of the results when new data become available and illustrates the magnitude of the new evidence that would be necessary to achieve a pooled estimate supporting the benefit of reducing amyloid levels. CONCLUSIONS: Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021. PMID: 33632704. doi:10.1136/bmj.n156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。